Gwenn Hansen Sells 5,394 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 5,394 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $20.00, for a total transaction of $107,880.00. Following the completion of the sale, the insider directly owned 115,005 shares of the company’s stock, valued at approximately $2,300,100. This trade represents a 4.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gwenn Hansen also recently made the following trade(s):

• On Thursday, April 30th, Gwenn Hansen sold 3,214 shares of Nurix Therapeutics stock. The stock was sold at an average price of $16.65, for a total transaction of $53,513.10.

Nurix Therapeutics Stock Performance

NRIX stock opened at $22.90 on Friday. Nurix Therapeutics, Inc. has a one year low of $8.19 and a one year high of $23.72. The firm has a market cap of $2.37 billion, a PE ratio of -7.25 and a beta of 1.86. The firm’s 50 day moving average price is $16.98 and its 200-day moving average price is $17.03.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings data on Wednesday, April 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03). The business had revenue of $6.25 million for the quarter, compared to analyst estimates of $14.25 million. Nurix Therapeutics had a negative return on equity of 64.21% and a negative net margin of 411.37%. Equities research analysts predict that Nurix Therapeutics, Inc. will post -2.88 EPS for the current fiscal year.

Hedge Funds Weigh In On Nurix Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Nurix Therapeutics by 11.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,804 shares of the company’s stock worth $593,000 after acquiring an additional 5,286 shares during the period. Millennium Management LLC boosted its holdings in Nurix Therapeutics by 106.2% in the first quarter. Millennium Management LLC now owns 874,399 shares of the company’s stock valued at $10,388,000 after purchasing an additional 450,262 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Nurix Therapeutics by 9.5% in the first quarter. Goldman Sachs Group Inc. now owns 507,471 shares of the company’s stock valued at $6,029,000 after purchasing an additional 44,002 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Nurix Therapeutics by 8.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 159,530 shares of the company’s stock worth $1,895,000 after purchasing an additional 12,817 shares in the last quarter. Finally, Creative Planning acquired a new position in Nurix Therapeutics during the 2nd quarter worth $187,000.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $32.00 price target on shares of Nurix Therapeutics in a research note on Wednesday, June 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $34.00 price objective on shares of Nurix Therapeutics in a research report on Monday, June 15th. Robert W. Baird lifted their target price on shares of Nurix Therapeutics from $26.00 to $33.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nurix Therapeutics in a research report on Tuesday, April 21st. Finally, BTIG Research upped their price target on Nurix Therapeutics from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, June 9th. Fourteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $32.20.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.